AH007

AH007 is a preclinical-stage precision oncology drug candidate being developed by Apricity Health. It is part of a proprietary pipeline of therapies identified through the company's 'Human-to-Human' (H2H) platform, which utilizes real-world clinical data and blood-based biomarkers to discover novel targets that drive resistance to current standard-of-care treatments. The program is specifically designed to address the needs of cancer patients who do not respond to existing therapies. As of early 2024, AH007 is in the early preclinical phase, with development efforts focused on target validation and establishing preclinical proof-of-concept. The specific molecular target and modality of the asset remain proprietary and have not been publicly disclosed.